Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

NCT05245071 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision, the decision is not related to any safety concern.

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: Tusamitamab ravtansine

Sponsor

Sanofi